TY - JOUR
T1 - Dietary fat, abdominal obesity and smoking modulate the relationship between plasma complement component 3 concentrations and metabolic syndrome risk
AU - Phillips, Catherine M.
AU - Kesse-Guyot, Emmanuelle
AU - Ahluwalia, Namanjeet
AU - McManus, Ross
AU - Hercberg, Serge
AU - Lairon, Denis
AU - Planells, Richard
AU - Roche, Helen M.
N1 - Funding Information:
This study was supported by the European Commission , Framework Programme 6 (LIPGENE): contract number FOOD-CT-2003-505944. The SU.VI.MAX study is registered as NCT00272428 at ClinicalTrials.gov. We thank all participants and authors for their contributions.
PY - 2012/2
Y1 - 2012/2
N2 - Objective: Chronic inflammation plays a role in the pathogenesis of metabolic syndrome (MetS) and cardiovascular disease (CVD). Complement component 3 (C3) is a novel cardiometabolic risk factor. Whether dietary fat intake modulates MetS risk conferred by elevated C3 concentrations is unknown. Our objective is to investigate the relationship between C3 concentrations and risk of the MetS and its phenotypes, and to further examine whether dietary fat intake modulates these relationships. Methods: Biochemical, dietary and lifestyle measurements were determined in the LIPGENE-SU.VI.MAX study of MetS cases and matched controls (n=1754). Results: Elevated C3 concentrations (>median) were associated with increased risk of impaired insulin sensitivity [OR 1.78, CI 1.34-2.36, P<0.0001], insulin resistance [OR 1.73, CI 1.31-2.89, P=0.0001], abdominal obesity [OR 2.15, CI 1.43-3.24, P=0.0002] and low HDL cholesterol [OR 1.40, CI 1.05-1.86, P=0.02] compared to low C3 concentrations. Increased MetS risk conferred by elevated C3 concentrations [OR 3.11, 95% CI 2.52-3.82, P<0.0001] was further accentuated among high dietary fat consumers [OR 4.80, 95% CI 2.77-8.33, P<0.0001] (particularly of saturated [OR 4.05, 95% CI 2.33-7.05, P<0.0001] and monounsaturated fat [OR 4.48, 95% CI 2.62-7.56, P<0.0001]), and smokers [OR 3.83, 95% CI 2.12-6.94, P<0.0001], however this effect was abolished in abdominally lean individuals [OR 1.46, 95% CI 0.69-3.14, P=0.33]. Conclusions: Dietary fat (intake and composition), abdominal obesity and smoking modulate the relationship between elevated plasma C3 concentrations and MetS risk.
AB - Objective: Chronic inflammation plays a role in the pathogenesis of metabolic syndrome (MetS) and cardiovascular disease (CVD). Complement component 3 (C3) is a novel cardiometabolic risk factor. Whether dietary fat intake modulates MetS risk conferred by elevated C3 concentrations is unknown. Our objective is to investigate the relationship between C3 concentrations and risk of the MetS and its phenotypes, and to further examine whether dietary fat intake modulates these relationships. Methods: Biochemical, dietary and lifestyle measurements were determined in the LIPGENE-SU.VI.MAX study of MetS cases and matched controls (n=1754). Results: Elevated C3 concentrations (>median) were associated with increased risk of impaired insulin sensitivity [OR 1.78, CI 1.34-2.36, P<0.0001], insulin resistance [OR 1.73, CI 1.31-2.89, P=0.0001], abdominal obesity [OR 2.15, CI 1.43-3.24, P=0.0002] and low HDL cholesterol [OR 1.40, CI 1.05-1.86, P=0.02] compared to low C3 concentrations. Increased MetS risk conferred by elevated C3 concentrations [OR 3.11, 95% CI 2.52-3.82, P<0.0001] was further accentuated among high dietary fat consumers [OR 4.80, 95% CI 2.77-8.33, P<0.0001] (particularly of saturated [OR 4.05, 95% CI 2.33-7.05, P<0.0001] and monounsaturated fat [OR 4.48, 95% CI 2.62-7.56, P<0.0001]), and smokers [OR 3.83, 95% CI 2.12-6.94, P<0.0001], however this effect was abolished in abdominally lean individuals [OR 1.46, 95% CI 0.69-3.14, P=0.33]. Conclusions: Dietary fat (intake and composition), abdominal obesity and smoking modulate the relationship between elevated plasma C3 concentrations and MetS risk.
UR - http://www.scopus.com/inward/record.url?scp=84855978209&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84855978209&partnerID=8YFLogxK
U2 - 10.1016/j.atherosclerosis.2011.11.007
DO - 10.1016/j.atherosclerosis.2011.11.007
M3 - Article
C2 - 22138144
AN - SCOPUS:84855978209
SN - 0021-9150
VL - 220
SP - 513
EP - 519
JO - Atherosclerosis
JF - Atherosclerosis
IS - 2
ER -